Emerging Biotech Saves Over $300,000 On Phase I Oncology Trial

An emerging biotech organization in the United States was experiencing operational difficulties within its Phase 1 Oncology programs due to complicated designs and sample requirements. The team also lacked visibility and control over the entire sample journey, which left them at risk for regulatory issues, protocol challenges, and lost data integrity.

Occurring during the COVID-19 pandemic, the issues were further compounded by economic pressures and supply chain inefficiencies. This would inevitably force the research team to rely on manual processes for clinical inventory, resupply, and sample management, and impacted the company’s ability to control costs. To overcome clinical inventory tracking, the biotech issued all the required kits for the entire length of the trial when the study launched. This, however, led to supply waste due to expiration or having too many of the wrong kits and not having enough kits for patients.

To save the study from almost certain failure, the biotech searched for help to simplify and automate current processes for managing and mitigating risks surrounding clinical inventory (laboratory kits, medical devices, ancillary supplies) and biological samples. Discover how one platform was able to transform chaotic clinical trial supply chains into protocol-specific operational workflows for sponsors, CROs, clinical research sites, and labs.